NewsResearch
mRNA Cancer Vaccines: Promising Research, Not Yet a Treatment You Can Get
Trials of personalized mRNA vaccines for melanoma have shown encouraging results. Here's what they are — and why they're still experimental.
A plain-language summary based on public reporting and trusted sources, linked below.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Two different things share one word
A vaccine that prevents infection teaches the immune system to recognize a germ before it arrives. The HPV and hepatitis B vaccines prevent cancer that way, by preventing the infection that causes it.
An mRNA cancer vaccine is not that. It is a treatment given to someone who already had cancer. NCI classes these as cancer treatment vaccines, a form of immunotherapy.
The confusion is understandable and it matters. Nobody is being offered a shot that stops melanoma from ever happening.
How the technology works
mRNA is messenger RNA, the molecule that carries instructions from DNA to the machinery that builds proteins.
Deliver mRNA into the body, and cells that take it up make the protein it codes for. Among those cells are dendritic cells, which NCI calls the sentinels of the immune system. They display the new protein to T cells. As one researcher quoted by NCI put it, dendritic cells act as teachers. They train T cells to find and kill cells carrying that marker.
Bare mRNA would be destroyed on arrival. So it is wrapped in lipid nanoparticles, tiny fatty spheres that protect the cargo. The COVID-19 vaccines used the same delivery method. The groundwork for them came from decades of cancer vaccine research.
What "personalized" means here
This is the part that makes these products unusual. Each one is made for a single person.
The process starts by sequencing a person's tumor to find mutations that could produce neoantigens. Neoantigens are abnormal proteins made by cancer cells and not by normal cells. That is what makes them safe targets.
Computer algorithms then predict which of those neoantigens are most likely to bind T cell receptors and provoke a response. A single vaccine can encode up to 34 of them.
Making one takes about 1 to 2 months, from tissue sample to finished product. Moderna's process runs at roughly 6 weeks. Our page on immunotherapy covers the wider family of treatments this belongs to.
What the melanoma trial found
KEYNOTE-942 is the trial behind the headlines. The ClinicalTrials.gov record, NCT03897881, shows a phase 2 study that opened in July 2019 and enrolled 267 people. The primary endpoint was recurrence-free survival.
Participants had stage III or IV melanoma completely removed by surgery. They then received either the vaccine with pembrolizumab, or pembrolizumab alone.
In December 2022 the companies reported the trial met its primary endpoint. The combination reduced the risk of recurrence or death by 44 percent, with a hazard ratio of 0.56 and a 95 percent confidence interval of 0.31 to 1.08.
In June 2024 they reported a planned analysis in 157 patients, at a median follow-up of 34.9 months. The risk of recurrence or death fell by 49 percent, hazard ratio 0.510. Recurrence-free survival at 2.5 years was 74.8 percent with the combination, against 55.6 percent with pembrolizumab alone.
Look at that first confidence interval again. It runs from 0.31 to 1.08, and 1.08 is above 1. A phase 2 trial of 157 patients gives a wide range, which is exactly why phase 3 exists.
Where it stands now
The phase 3 trial, NCT05933577, opened on 19 July 2023 and plans to enroll 1,089 people with high-risk melanoma. Its primary endpoint is again recurrence-free survival. The record lists it as active and no longer recruiting, which means results are pending, not published.
Studies in other cancers are running too. They include non-small cell lung cancer, kidney cancer, bladder cancer, and a skin cancer called cutaneous squamous cell carcinoma.
The record on other tumor types is genuinely mixed. NCI describes a trial of a personalized mRNA vaccine with a checkpoint inhibitor in advanced head and neck cancer. The study first included colorectal cancer patients, and that group did not appear to benefit. Among the first 10 head and neck patients, 2 had complete responses and 5 had tumors shrink. Ten patients is a signal to follow, not a result.
What this means if you or someone you love has melanoma
None of these products is approved. They are available only through clinical trials, and trials have entry criteria that most people will not meet. Our page on what are clinical trials explains how enrollment works.
The proven ground is elsewhere. Surgery removes the melanoma. Immunotherapy after surgery, pembrolizumab included, is established care for high-risk disease. It is the arm these trials are trying to beat.
Early detection still beats everything downstream. NCI's ABCDE guide names the signs: Asymmetry, irregular Border, more than one Color, Diameter usually larger than 6 millimeters, and Evolving over time. NCI also lists a mole that itches, oozes, bleeds, or ulcerates, and new moles growing beside an existing one. Any of these is worth a doctor's look. Our page on melanoma covers the checks in more detail.
What this trial cannot tell you
Recurrence-free survival counts whether cancer comes back. It is not overall survival, and the phase 2 results say nothing about how long people live.
The design also always includes pembrolizumab. There is no arm testing the vaccine alone, so nothing here supports it as a standalone treatment.
The evidence is confined to melanoma after complete surgical removal. It does not extend to melanoma that cannot be removed, to earlier-stage disease, or to other cancers, where the trials are still running.
And the strongest results so far come from company press releases about a mid-stage trial. That is a fair place to be excited. It is a poor place to make decisions. The phase 3 answer is not in.
Sources
- NCI, How mRNA Vaccines Might Help Treat Cancer — https://www.cancer.gov/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer
- NCI, Immunotherapy to Treat Cancer — https://www.cancer.gov/about-cancer/treatment/types/immunotherapy
- Moderna and Merck, mRNA-4157/V940 met primary efficacy endpoint in Phase 2b KEYNOTE-942 — https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
- Moderna and Merck, 3-year data for mRNA-4157 (V940) with KEYTRUDA — https://www.merck.com/news/moderna-merck-announce-3-year-data-for-mrna-4157-v940-in-combination-with-keytruda-pembrolizumab-demonstrated-sustained-improvement-in-recurrence-free-survival-distant-metastasis-free-su/
- NCI PDQ, Melanoma Treatment (Patient Version) — https://www.cancer.gov/types/skin/patient/melanoma-treatment-pdq
- ClinicalTrials.gov, KEYNOTE-942 (NCT03897881) — https://clinicaltrials.gov/study/NCT03897881
- ClinicalTrials.gov, V940-001 Phase 3 in high-risk melanoma (NCT05933577) — https://clinicaltrials.gov/study/NCT05933577
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Cancer vaccine research. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.